Best Biotech ETF: Top Picks for 2025 Investors

Top Biotech ETFs to Watch in 2025

Exploring biotechnology investments requires understanding the various ETFs that capture the innovation and growth potential of this fast-evolving sector. Biotechnology ETFs provide access to companies advancing healthcare through gene editing, genetic therapies, molecular diagnostics, and more. Whether seeking broad exposure or targeted investments, selecting the right ETF is essential for portfolio diversification and capitalizing on industry trends. This article presents a selection of prominent biotech ETFs, highlighting their focus areas and investment strategies to help inform better investment decisions.

ARK Genomic Revolution ETF (ARKG)

This actively managed ETF targets companies specializing in gene editing, genetic therapies, and molecular diagnostics. It appeals to investors aiming to benefit from the rapidly expanding genomics sector. ARKG emphasizes innovation by investing in firms utilizing technologies such as CRISPR to transform healthcare.

• Gene Editing: Companies utilizing CRISPR and other advanced methods to modify genetic material.
• Genetic Therapies: Enterprises developing treatments to correct genetic disorders through innovative therapies.
• Molecular Diagnostics: Firms focused on early disease detection and personalized medicine based on genomic data.

With a research-driven approach, ARKG offers exposure to high-growth potential stocks shaping the future of medicine.

iShares Nasdaq Biotechnology ETF (IBB)

This ETF provides broad exposure to a diversified portfolio of biotech stocks listed on the NASDAQ. It includes large-cap established companies alongside mid-cap and small-cap firms with promising growth potential. IBB balances stability with innovation across the biotechnology industry.

Investment Highlights

• Diversification: Combines large-cap biotech firms with smaller companies showing growth opportunities.
• Growth Potential: Many of the smaller firms included in this ETF are developing innovative products.
• Market Performance: Tracks key indices representing overall biotechnology trends.

SPDR S&P Biotech ETF (XBI)

XBI employs an equal-weighted strategy that favors smaller biotech companies alongside larger entities. This structure enables investors to benefit from a wide range of innovative firms actively advancing medical research.

• Innovation Focus: Smaller biotech firms working on groundbreaking treatments.
• Diversification Benefits: Equal weighting reduces the impact of any single stock.
• Aggressive Growth Potential: Exposure to high-reward opportunities in emerging biotech companies.

First Trust NYSE Arca Biotechnology Index Fund (FBT)

FBT tracks the NYSE Arca Biotechnology Index, investing primarily in U.S.-based biotech companies at various development stages, from startups to established industry leaders.

Investment Strategy

• Startups: Investing in new biotech companies that have a high potential for profit.
• Mature Companies: Investments in established companies generate steady revenues.
• Biopharmaceutical Advancements: Focus on drug discovery, gene therapies, and new medical technologies.

This ETF provides a balanced approach by integrating early-stage innovation with established biotech players.

Invesco Dynamic Biotechnology & Genome ETF (PBE)

PBE focuses on biotechnology and genome innovation using a smart beta strategy. It selects stocks based on fundamental factors like earnings momentum and quality while managing risk through diversification.

Smart Beta Strategy

• Earnings Momentum: Targets companies with strong recent earnings performance.
• Quality Indicators: Chooses financially sound firms for investment stability.

This strategy aims to balance risk while capturing emerging biotechnological advancements.

Tortoise Global Cloud Infrastructure Fund (TCLD)

Although not a traditional biotech fund, TCLD invests significantly in health technology companies leveraging cloud computing for healthcare applications. This provides indirect exposure to advancing biotechnological solutions.

Advantages

• Diverse Portfolio:  Includes various sectors with an emphasis on health tech innovation.
• Growth Potential: As cloud technologies become more widely used by healthcare providers.
• Risk Management: Offers broad market exposure and reduces direct biotech investment risks.

Defiance Next Gen Altered Experience ETF (AUGR)

AUGR targets emerging trends in personalized medicine and virtual advancements within pharmaceuticals, aiming to transform patient treatment experiences worldwide.

Investment Areas

• Personalized Therapies: Investments in companies developing tailored biopharmaceutical treatments.
• Telemedicine Integration: Firms leveraging telehealth to enhance patient accessibility.
• Wearable Health Technologies: Companies producing real-time health monitoring devices.

This ETF focuses on transformative technologies that are redefining patient care.

Lattice Emerging Markets Biotech Strategy Fund (LABF)

LABF provides international diversification by investing in biotechnology firms located in emerging markets outside North America and Europe.

Global Exposure

• Innovation in Emerging Markets: Targets biotech companies from regions like China, India, and Brazil.
• Diversification Benefits: Spreads risk across different economies.
• Growth Opportunities: Capitalizes on cost advantages and rising biotech investment in emerging markets.

This fund offers unique access to biotech developments occurring beyond traditional Western markets.

---

Voted "Best Overall Budgeting App" by Forbes and WSJ

Monarch Money helps you budget, track spending, set goals, and plan your financial future—all in one app.

Get 50% OFF your first year with code MONARCHVIP

View More

---

Final Thoughts on Biotech ETF Investment Options

Biotechnology ETFs present a diverse range of investment opportunities, from high-risk startups to established market leaders driving healthcare innovation. Choosing the right ETF depends on individual investment goals, risk tolerance, and interest in specific biotech subsectors. Whether seeking aggressive growth, international diversification, or balanced exposure, the ETFs described here offer multiple avenues to engage with this dynamic industry shaping the future of medicine.

Frequently Asked Questions

What factors should I consider when choosing a biotech ETF?

Investors should evaluate the ETF’s focus areas, management style, diversification, and risk tolerance. Understanding whether the ETF targets early-stage startups, established firms, or a mix is important. Additionally, reviewing performance history and fees helps in making informed choices aligned with investment goals.

How does an equal-weighted ETF like XBI differ from market-cap-weighted ETFs?

Equal-weighted ETFs assign the same importance to each stock, reducing dominance by large companies and increasing exposure to smaller firms. This can offer more growth potential but may also lead to higher volatility compared to market-cap-weighted ETFs that favor larger companies.

Can biotech ETFs provide international exposure?

Yes, some ETFs like LABF focus on emerging market biotechnology firms outside traditional regions, offering geographic diversification. This exposure allows investors to tap into biotech growth occurring globally, which may provide additional opportunities and risk diversification.

Is investing in biotech ETFs considered high risk?

Biotech investments often carry higher risks due to regulatory challenges, product development uncertainties, and market volatility. However, ETFs that include a mix of established companies and startups can help balance this risk. It is essential to assess personal risk tolerance before investing.